Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?| Positive | ||
| Negative | ||
| Uncertain | ||
| Constraining | ||
| Legalese | ||
| Litigous | ||
| Readability |
H.S. junior Avg
|
|
New words:
accrual, advocacy, arithmetic, Arzneimittel, Assumption, aware, ballot, breakdown, Bristol, Bulletin, capture, caution, Chamber, Chem, CLS, codified, Commerce, confirmed, correlated, debating, display, diversification, drew, eleven, endorsement, enterprise, Error, flat, FTC, German, GmbH, imply, input, internationally, investor, Jersey, KG, LG, MA, macroeconomic, maker, margin, medium, Merck, month, Nevada, nonpublic, OND, OTC, Overnight, overstated, overstatement, Page, PDUFA, prearrange, professional, project, proportionate, quotation, RenazorbTM, rounding, SAB, SOFR, sponsorship, Squibb, strongly, summary, Swissmedic, switching, text, thereto, TM, trailing, uncompensated, understated, understatement, unfair, unpermitted, unrecognized, unremediated, Washington, weighted, withheld, wrote
Removed:
automatic, circumstance, close, compounding, consecutive, continually, drawn, Evergreen, floating, forfeited, intention, leasehold, lesser, merge, mitigated, Multiplier, notifying, participating, preservation, qualitative, quantitative, reserved, reverse, RionaTM, settled, split, suggest, test, titled, undiscounted, unexercised, unobservable, unrestricted, utilizing, VafseoTM, view
Filing tables
Filing exhibits
Related press release
Associated AKBA transcripts
AKBA similar filings
Filing view
External links
| Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) is the type of information that the registrant treats as private or confidential. Double asterisks denote omissions. | ||
Exhibit 10.4
[Akebia Letterhead]
May 3, 2023
By Email
[First Name Last Name]
[Address]
Dear [First Name Last Name]:
Upon your execution of this Amendment, the following amendments will be made to your Separation Agreement with Akebia Therapeutics, Inc. (“Akebia”) dated May 5, 2022 (as previously amended, the “Separation Agreement”)
A.Paragraph 1(ii) of the Separation Agreement shall be replaced in its entirety with the following:
(ii) Separation Date. Unless your employment is terminated by the Company for Cause or by you for Good Reason (as those terms are defined in your Executive Severance Agreement dated March 3, 2014, the “ESA”), you will remain employed until July 28, 2023; unless, [**], but in any event no later than January 26, 2024 (as applicable, the “Separation Date”). The Separation Date may be modified only upon mutual agreement between you and the Company.
B.Exhibit A of your Separation Agreement shall be replaced in its entirety with the Exhibit A in Appendix 1 attached hereto.
All other terms and conditions of the Separation Agreement shall remain in full force and effect.
Very truly yours,
AKEBIA THERAPEUTICS, INC.
John P. Butler
President and Chief Executive Officer
Accepted and Agreed to Under Seal:
[First Name Last Name]
Dated: , 2023